Numerous qualitative and quantitative techniques can be used to test sensory nerves and pain in both research and clinical settings. The current study demonstrates a quantitative sensory testing protocol using techniques to measure tactile sensation and pain threshold for pressure and heat using portable and easily accessed equipment. These techniques and equipment are ideal for new laboratories and clinics where cost is a concern or a limiting factor. We demonstrate measurement techniques for the following: cutaneous mechanical sensitivity on the arms and legs (von-Frey filaments), radiant and contact heat sensitivity (with both threshold and qualitative assessments using the Visual Analog Scale (VAS)), and mechanical pressure sensitivity (algometer, with both threshold and the VAS). The techniques and equipment described and demonstrated here can be easily purchased, stored, and transported by most clinics and research laboratories around the world. A limitation of this approach is a lack of automation or computer control. Thus, these processes can be more labor intensive in terms of personnel training and data recording than the more sophisticated equipment. We provide a set of reliability data for the demonstrated techniques. From our description, a new laboratory should be able to set up and run these tests and to develop their own internal reliability data.
Introduction
Chronic pain conditions are a worldwide clinical problem. More than 1.5 billion people worldwide suffer from chronic pain, and approximately 5% of the global population suffers from neuropathic pain, with incidence rates increasing with age 1 . In America, it is estimated that pain affects more people than diabetes, heart disease, and cancer, combined 2 . While awareness of this problem is increasing, treatments are not always successful, can be expensive, and may have serious side effects, including addiction. Research on treatments is ongoing, but as pain varies greatly between individuals, pain measurement for research or diagnosis can be problematic. In particular, the reliance on qualitative approaches, such as the Visual Analog Scale (VAS), for determining treatment efficacy has been problematic because of the subjective and personal nature of pain 3 . As more research laboratories and smaller clinics around the world answer questions about and treat pain, measures that are accurate, consistent, portable, quantitative, and affordable are in great demand.
A key distinction in pain measurement is acute versus chronic pain. Acute pain is a normal response to injury, infection, or another noxious stimulus. Acute pain normally resolves with treatment and time, and the pain location is usually site-specific. Chronic pain, however, can be related to an initial bout of acute pain, or it can be idiopathic. Chronic pain may relate to the site of injury, but it is often widespread throughout the body 4 . Chronic pain can last for weeks, months, and even years, causing substantial physical, psychological, and monetary burdens on patients and their families, employers, and societies. The ability to identify and quantify pain is critical for correct diagnosis, evaluation of ongoing treatment, and development of new analgesic treatments. Quantitative and qualitative sensory testing are thus critical for diagnosis and treatment.
Several methods can be used to examine peripheral sensation and pain: nerve conduction velocity (NCV), somatosensory evoked potentials (SEP), skin biopsies, and quantitative sensory testing (QST). Clinicians also routinely use bedside neurologic sensory testing, but this testing is not calibrated and does not use a standardized set of instructions 5 . Exams of NCV and SEP can be informative, but compared to QST, they require highly specialized equipment, typically only examine large nerve fibers, only measure loss of function, and do not test the entire somatosensory system 6, 7 . Skin biopsies are used to assess nerve fiber density, but compared to QST, they are invasive and require tissue processing and microscopy time, which could take several days to accomplish 14 . The unit is modular, and additional sensory testing devices can be added. In their study, Angst et al. also demonstrate pressure sensory testing with the use of Punctuated Pressure Probes, which were custom built. While these probes should offer more consistent results, few laboratories or clinics have them.
The current protocol demonstrates QST measures for chronic pain: von Frey filaments for cutaneous sensory testing, a radiant ("Hargreaves" method) and contact heat technique, and pressure algometry for deep tissue pain. These QST measurements are not unique. Rather, they are the most common and generally accepted measurements for human sensory testing in medical clinics, hospitals, and research laboratories 13, 15, 16 . Mechanical and thermal stimulation are used to examine cutaneous and deep sensation. These measures, furthermore, include the evaluation of both small and large fiber sensitivity for normal sensation and pain. To assess deep tissue pain (muscle), pressure algometry is used, which is the most frequently applied technique for the quantification of pain in soft tissue such as muscles 17, 18 . Both A-delta and C fibers mediate pain induced by pressure stimulation 19 . Stimulation of both fibers is an advantage and a disadvantage, in that it examines multiple pathways, making it a good overall measure, but it is also less specific. To examine touch sensitivity, mechanical stimulation of skin with von Frey filaments is used because they are one of the most commonly used sensory devices in pain and medical neural clinics. Von Frey filaments stimulate A-beta fibers, 20 but are not specific as both low threshold mechanoreceptors and nociceptors can be activated 21 . The use of these filaments has been criticized, mainly because of potential variability of the application procedure (degree of filament indention or accidental movement of the hand) and concerns that the mechanical filament characteristics may change over time 22, 23 . This protocol addresses these issues by providing detailed instructions with a script and calibration of filaments.
For thermal pain, radiant heat using the "Hargreaves" method (visible light and ramping temperature) and a heat block to examine contact heat are used. Contact and radiant heat activate thermal receptors differently and can even confound one another. It has been shown that dynamic contact can inhibit thermal nociception 24 . This is similar to the concept of thermal referral, in which touch contributes to normal temperature perception [25] [26] [27] . Therefore, one measure of thermal sensation and two measures of thermal pain are included. First, radiant heat is used to determine the threshold for temperature change detection (starting from room temperature). Second, the radiant heat source is used to determine the threshold for heat pain. The detection of warm thermal change (non-nociceptive) is mediated in part by transient receptor potential (TRP) channels on C fibers, while heat pain is mediated by TRPV1/V2 and other higher-threshold channels on C and A-delta fibers [28] [29] [30] . At threshold determination, rapid skin heating activates first A-delta fibers, corresponding to the "first pain," followed by a C fiber-mediated "second pain," described as "throbbing, burning, or swelling" 31 . Heating gives a preferential activation of C fibers and is the best evaluation of second pain 32 . In the contact heat assay, a constant nociceptive temperature is applied to determine the qualitative intensity and affective aspects of pain.
Another variable considered in developing the QST protocol is anatomical location. For acute or location-specific pain, the anatomical site of the pain is typically used for testing. Because the protocol was designed with chronic pain conditions in mind, we take a more global approach. The protocol assesses sensation on the forearm and leg instead of the hand, as it has been shown that heat pain thresholds are significantly higher on the hand than on the forearm 33 and that thermal nociception can be perceived on the hand, although less frequently and less intensely than on the forearm 24 . While the protocol was designed for the majority of chronic pain conditions, we caution users that some chronic pain conditions affect specific anatomical regions, and this should be taken into account when modifying the protocol for a specific patient population.
While these QST measures are the most commonly used and are accepted as some of the most reliable, they are inexpensive and common enough that most clinics and research laboratories might already have access to them, can afford them, and can transport them. This QST protocol is useful to any laboratory or clinic where measures are needed for humans with chronic pain. To date, there are currently no published visual reports demonstrating a protocol for the use and reliability of these measures. Based upon this protocol demonstration and tips on improving reliability, a laboratory or clinic could easily examine their own test-retest reliability. Because many clinics will need to utilize several technicians to measure all patients, inter-rater reliability data would be useful in selecting a protocol. We include a small set of data that suggests that the protocol has good reliability, but each clinic and laboratory is strongly advised to use this as an example, as each clinic and each patient population with chronic pain is unique.
Notes on injury risk for sensory and pain testing:
Risk of injury related to cutaneous mechanical testing is extremely rare and unlikely. Mechanical testing is safe and widely used. Risks to the individual are minimal because 1) this is not a painful or noxious stimulus; 2) subjects are instructed that they may stop any procedure at any time, with no adverse consequences; and 3) the level of sensation experienced by subjects is well below their tolerance level and threshold for pain.
Risk of injury related to thermal pain testing is minimal. Thermal testing is safe and widely used. While thermal testing does produce pain, risks to the individual are minimal because 1) the pain is transient in nature and generally subsides immediately after the procedure; 2) subjects are instructed that they may stop any procedure at any time, with no adverse consequences; and 3) the level of pain experienced by subjects is below their tolerance level. With Hargreaves thermal stimulation, there is a very slight risk of receiving a burn, but this is minimized by the following: 1) the positive lockout of stimulus parameters above 50 °C; 2) the built-in shutdown system in the stimulator that prevents the delivery of prolonged or high-intensity stimuli (20 sec); and 3) the electronic thermometer that measures the temperature at the glass surface before and Risk of injury related to pressure pain testing is minimal. Pressure testing is safe and widely used. While pressure testing does produce pain, risks to the individual are minimal because 1) the pain is transient in nature and generally subsides immediately after the procedure; 2) subjects are instructed that they may stop any procedure at any time, with no adverse consequences; 3) the level of pain experienced by subjects is below their tolerance level; and 4) the pain applied is never more than that subject's pain threshold, which is well below any pressure that could cause damage. A rare side effect of pressure testing is bruising at the stimulus site. In this situation, a subject should not be retested at the bruised site. The chance for bruising can be minimized by study exclusion of individuals that bruise easily or are taking blood thinners.
During the enrollment period, participants are given a full description of all sensory and pain measures that will be used. With initial consent, all participants are allowed to experience all sensory and pain measures before full enrollment. All sensory and pain assays are based on wellestablished assays used in both healthy human participants and in chronic pain patients 34 . All assays involve either innocuous (non-painful stimuli) or acute noxious stimuli (painful stimuli) that do not damage tissue. The time between different tests is >5 min, to allow the subject to rest and to reduce the potential for sensory fatigue or sensitization. The sequential order of tests is the same during each testing session. Specific sites of testing are limited to the T1 dermatome on the left and right forearms and L3/S2 dermatome on the left and right calves. All sites for testing are marked with a marker, and individual sites are spread out to avoid overlapping receptive field activation (Figure 1) . See the Materials and Equipment Table for the full materials list. For retest reliability studies, individual subjects were tested by two experimenters in a single day.
Protocol
All tests with human subjects should be approved by the Institutional Review Board at the individual institution. All testing described for the current study was approved by the Duquesne University Institutional Review Board for human subject research. Training for and descriptions of each measure are as follows:
Cutaneous Mechanical Sensitivity Assay 13
NOTE: Enrolled participants are asked to sit in a chair, with support provided for the extremity to be tested. The assay involves determining the sensitivity threshold for innocuous cutaneous stimulation. Stimulation is provided with standard sensory evaluator von Frey filaments (see the equipment section). These small nylon filaments each apply a single force (ranging from 0.078 mN (0.008 g) to 4.08 mN (1.0 g)).
1. Before the start of the first experimental trial, allow the participant to feel and manipulate the filaments. Give the filament to the participant and let them gently bend it against the skin of their hand. 2. During each trial, ask the subject to look away from their forearm or calf. Apply the filament to the subject's forearm or calf until it bows, and ask if they feel the filament. 3. Starting with the smallest filament (0.078 mN; below the sensory threshold for human detection), conduct five trials on the subject's forearm or calf for each filament. 1. With each filament (e.g., the 0.078 mN filament), apply the filament four times in the "positive" trials. 2. For the other trial, do not apply the filament, but still ask the subject if they feel the filament. NOTE: This "negative" trial will be randomly inserted with the four "positive" trials and is designed to test for false responses (i.e., the subject thinks they feel something even though no stimulus is applied). This is necessary for sensory threshold testing, because random noise in the sensory system and/or other stimuli (e.g., a light breeze) can cause a false response.
4. If a subject detects ≥3 of the positive trials and 0 negative trials for a filament, then record that filament as the subject's "mechanical sensory threshold" on the data form. 5. For a single filament, if the subject detects <2 of the real trials and/or >0 of the false trials, then start another round of 5 trials with the nextbiggest filament until the sensory threshold is reached. NOTE: Sensory thresholds vary for human participants, but in experience, they typically range from 1.57-9.81 mN (data not shown). This force is enough to feel light innocuous pressure. Typical testing time for each body part (forearm and calf) is about 5 min. It is also possible to measure needle-like pain with these filaments, but this usually entails using larger-diameter filaments.
Radiant Heat Sensitivity Assay 35
NOTE: Enrolled participants are asked to sit in a chair, with support provided for the extremity to be tested. The assay involves determining the sensitivity threshold for non-painful heat change and for painful thermal stimulation. Stimulation is provided with a radiant heat device 35 . This device uses a focused light beam to slowly heat a subject's skin through a piece of 0.64-mm-thick safety glass (see below in the instrument section).
1. Before the start of the training and experimental trials, show the device to the subject; allow them to feel the stimulus with their hand. 2. Ask the subject to rest their forearm or calf on the room temperature glass plate, which should be covered with a rubber-insulating sheet except for the small window for stimulus presentation. NOTE: The insulating sheet allows the subject to focus on the stimulus presentation without the cooling sensation associated with placing one's body against a room-temperature object. 3. Using a mirror, position the light source under a marked area on the subject's forearm or calf (Figure 1) . NOTE: When the leg or arm is raised from the surface of the glass, the thermal stimulus automatically stops and the time since the beginning of the trial is then recorded as the "latency to respond." 4. Complete two trials for each test on each limb (innocuous temperature detection and pain threshold) in two distinct marked areas to avoid retesting at a single site. 5. For the innocuous temperature detection trial, ask the subject to raise their leg or arm or depress the "stop" button when they feel the temperature change. 1. Set the device so that the typical withdrawal threshold occurs at approximately 10 sec into the trial and so that the device shuts off after 20 sec. To accomplish this withdrawal threshold, set the device to ramp the temperature such that the stimulus reaches 47 °C at 10 sec. NOTE: For innocuous temperature detection trials, the typical temperature on the glass at threshold is 37 °C (99 °F). In the pain threshold trial, subjects are told to raise their leg or arm or depress the "stop" button when they feel the stimulus transition from "innocuous warmth or heat" to "painful heat." The typical temperature on the glass at threshold is ~47 °C (121 °F). The maximum temperature of the trial at the 20 sec cutoff time point is 50 °C, which is well below the cumulative temperature that causes tissue damage in humans 36 .
6. Use the constant temperature assay 28 (heat block) to evaluate both the quality and unpleasantness of thermal pain. Using the heat block, set the temperature to 45 °C for the stimulus. NOTE: 45 °C is a standard temperature that is the typical minimal stimulus necessary to feel thermal pain and is known to activate TRPV1 nociceptive receptors 2) ] for the seven pain and sensitivity measures. Individual subjects (n = 6) were assayed by two investigators (one male and one female). All tests were performed on the same day (30 min apart). ICC(3,2) and corresponding P-values are given for each measure. Please click here to view a larger version of this table.
Discussion
We have demonstrated cost-effective and simple qualitative and quantitative sensory tests that can be used to assess mechanical sensation, thermal sensation and pain, and pressure pain in human subjects. The value of these assays is their ease of implementation and low amount of necessary training time. Each experimenter received a minimal amount of training (one trial observation and one trial implementation). Thus, multiple technicians could be trained in one day. The results suggest strong inter-experimenter and within-subject reliability. Depending on the number of tests that each lab uses, statistical correction for multiple ICC testing is advisable.
One measure of inter-experimenter reliability, mechanical sensitivity, did not reach statistical significance (ICC = 0.76, p = 0.08). We reexamined the data collection procedure laboratory notes for two of the subjects and found no abnormalities in data collection. While it is likely that a larger sample size would have reached statistical significance, we think that this is noteworthy for three reasons. First, pain, a subjective experience, is difficult to measure, and efforts to standardize testing cannot be overemphasized. Second, the possibility of a gender bias in pain testing should be considered when conducting these measures. Finally, there is a possibility of a proportional bias, in that at the end of the spectrum considered "high sensitivity," the tests may become less reliable. A more extensive study would need to be conducted to correctly ascertain if this bias exists.
Critical steps in ensuring consistency are reading from a script when explaining tests to a participant; checking the force exerted by monofilaments; and making efforts to ensure that that the intensity, frequency, duration, and localization of the experimental stimuli involved are precisely controlled. Additionally, room temperature could be a factor while measuring sensation, so room temperature should be controlled and recorded. For these results, although it is impossible with this design to truly disambiguate within-subject and intra-experimenter reliability, the fact that a subject demonstrates consistent thresholds suggests that these assays are stable enough for use in clinical and research trials. Furthermore, this is an important finding because it demonstrates a lack of retesting sensitization or sensitivity fatigue.
Most importantly for large clinics, these data show that multiple trained experimenters can reliably implement these tests, and that gender differences between experimenters and subjects or patients are unlikely to affect the results. The protocol is thus broadly applicable to clinics or research laboratories where employee turn-over and the training of new technicians occurs, as this is unlikely to affect the results of the QST assays.
An important limitation of the current study is its sampling of healthy volunteers. There are numerous chronic pain syndromes, and each patient population is unique. Rather than limit our study to one type or classification of chronic pain, we decided to test healthy volunteers as a general model. Each clinic or laboratory is advised to conduct their own internal analysis for a specific patient population.
The overall significance of the protocol is that these assays are reasonably priced and easy to include in typical sensory testing protocols (research or clinical); they are also reliable, even across examiners. The only real limitation is the need for some training and for manual recording of all data. We did not find troubleshooting or modifications to be necessary, so long as the proper equipment is available.
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